<DOC>
	<DOCNO>NCT00171158</DOCNO>
	<brief_summary>This extension II study allow follow-up disease treatment imatinib mesylate allow patient continue receive imatinib mesylate .</brief_summary>
	<brief_title>An Extension Study Safety Anti-leukemic Effects Imatinib Mesylate Patients ( Male Female â‰¥18 Years ) With Ph + CML Blast Crisis</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Successful completion CSTI571A0102E1 study Written inform consent extension CSTI571A0102E2 Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>Blast crisis</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>